Gerber L - Search Results

1

Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Gerber L, Nader F, Hunt S. Younossi ZM, et al. Among authors: gerber l. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1349-59.e13. doi: 10.1016/j.cgh.2013.11.032. Epub 2013 Dec 6. Clin Gastroenterol Hepatol. 2014. PMID: 24316172

2

Health-related quality of life in patients with non-alcoholic fatty liver disease.

Dan AA, Kallman JB, Wheeler A, Younoszai Z, Collantes R, Bondini S, Gerber L, Younossi ZM. Dan AA, et al. Among authors: gerber l. Aliment Pharmacol Ther. 2007 Sep 15;26(6):815-20. doi: 10.1111/j.1365-2036.2007.03426.x. Aliment Pharmacol Ther. 2007. PMID: 17767465

3

Disparities in activity level and nutrition between patients with chronic hepatitis C and blood donors.

Moon J, Kallman J, Winter P, Srishord M, Fang Y, Gerber L, Younossi Z. Moon J, et al. Among authors: gerber l. PM R. 2012 Jun;4(6):436-41. doi: 10.1016/j.pmrj.2012.02.020. Epub 2012 Apr 28. PM R. 2012. PMID: 22543035

4

Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study.

Gerber L, Otgonsuren M, Mishra A, Escheik C, Birerdinc A, Stepanova M, Younossi ZM. Gerber L, et al. Aliment Pharmacol Ther. 2012 Oct;36(8):772-81. doi: 10.1111/apt.12038. Epub 2012 Sep 8. Aliment Pharmacol Ther. 2012. PMID: 22958053

5

Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease.

Otgonsuren M, Stepanova M, Gerber L, Younossi ZM. Otgonsuren M, et al. Among authors: gerber l. Dig Dis Sci. 2013 Apr;58(4):1132-40. doi: 10.1007/s10620-012-2446-3. Epub 2012 Nov 10. Dig Dis Sci. 2013. PMID: 23143735

6

Reply: To PMID 23143735.

Gerber L, Otognsuren M, Younossi Z. Gerber L, et al. Dig Dis Sci. 2013 May;58(5):1435-7. Dig Dis Sci. 2013. PMID: 23841147 No abstract available.

7

Multiple factors predict physical performance in people with chronic liver disease.

Loria A, Doyle K, Weinstein AA, Winter P, Escheik C, Price J, Wang L, Birerdinc A, Baranova A, Gerber L, Younossi ZM. Loria A, et al. Among authors: gerber l. Am J Phys Med Rehabil. 2014 Jun;93(6):470-6. doi: 10.1097/PHM.0000000000000050. Am J Phys Med Rehabil. 2014. PMID: 24398583

8

Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.

Gerber L, Estep M, Stepanova M, Escheik C, Weinstein A, Younossi ZM. Gerber L, et al. Clin Gastroenterol Hepatol. 2016 Jan;14(1):156-64.e3. doi: 10.1016/j.cgh.2015.07.035. Epub 2015 Aug 1. Clin Gastroenterol Hepatol. 2016. PMID: 26241510

9

Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.

Younossi ZM, Elsheikh E, Stepanova M, Gerber L, Nader F, Stamm LM, Brainard DM, McHutchinson JG. Younossi ZM, et al. Among authors: gerber l. J Viral Hepat. 2015 Dec;22(12):977-82. doi: 10.1111/jvh.12448. Epub 2015 Aug 17. J Viral Hepat. 2015. PMID: 26280786 Clinical Trial.

10

Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C".

Gerber L, Younossi Z. Gerber L, et al. J Hepatol. 2015 Dec;63(6):1534-5. doi: 10.1016/j.jhep.2015.08.035. Epub 2015 Sep 12. J Hepatol. 2015. PMID: 26375244 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

762 results

Search Page

Filters